Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
Primary Purpose
Hemophilia A
Status
Recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Factor IX
Sponsored by
About this trial
This is an interventional basic science trial for Hemophilia A focused on measuring Hemophilia A with inhibitors, In vitro, Emicizumab
Eligibility Criteria
Inclusion Criteria:
- Signed Informed Consent/Assent Form
- Male patients, Age 12 years and older at time of signing Informed Consent Form
- Ability to comply with the study protocol, in the investigator's judgment
- Diagnosis of severe hemophilia A and are receiving emicizumab prophylaxis, on a weekly maintenance regimen
Exclusion Criteria:
- Not able to sign consent
- Not willing to provide extra blood for the experiments.
- Patients carrying the diagnoses of other coagulopathies in addition to hemophilia A
- Patients that have received any hemostatic agent within 5 half-lives of the blood draw. This applies to any agent that might have been used for any reason prior to the blood draw and might affect the global hemostasis.
Sites / Locations
- Tulane University Lakeside Hospital and ClinicsRecruiting
- University Medical Center New OrleansRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Patient Group
Arm Description
In vitro spiking experiments will be realized in plasmas from patients with severe haemophilia A on emicizumab using increasing concentrations of factor IX (rFIX), Activated prothrombin complex (aPCC) and recombinant VIIa (rFVIIa).
Outcomes
Primary Outcome Measures
Determine the homeostatic effect of adding Factor IX concentrate to the plasma of patients with Hemophilia A with inhibitors on emicizumab using peak thrombin
Peak thrombin is a thrombin generation profile. The investigators will compare the peak thrombin obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with aPCC and rFVIIa on emicizumab prophylaxis.
Determine the hemostatic effect of Factor IX concentrates and recombinant porcine FVIII when added to the plasma of patients with Hemophilia A with inhibitors on emicizumab using peak thrombin
The investigators will compare the peak thrombin obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with recombinant porcine FVIII on emicizumab prophylaxis.
Determine the homeostatic effect of adding Factor IX concentrate to the plasma of patients with Hemophilia A with inhibitors on emicizumab using Endogenous Thrombin Potential (ETP)
Endogenous Thrombin Potential is a thrombin generation profile. The investigators will compare the Endogenous Thrombin Potential obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with aPCC and rFVIIa on emicizumab prophylaxis.
Determine the hemostatic effect of Factor IX concentrates and recombinant porcine FVIII when added to the plasma of patients with Hemophilia A with inhibitors on emicizumab using Endogenous Thrombin Potential (ETP)
The investigators will compare the Endogenous Thrombin Potential obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with recombinant porcine FVIII on emicizumab prophylaxis.
Secondary Outcome Measures
Full Information
NCT ID
NCT05281718
First Posted
February 11, 2022
Last Updated
November 14, 2022
Sponsor
Tulane University
Collaborators
Genentech, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT05281718
Brief Title
Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
Official Title
An in Vitro Pilot Study of the Role of Factor IX as an Alternative to Bypassing Agents in the Treatment of Breakthrough Bleeds in Patients With Hemophilia A and Inhibitors Treated With Emicizumab.
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 1, 2022 (Actual)
Primary Completion Date
July 2024 (Anticipated)
Study Completion Date
July 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Tulane University
Collaborators
Genentech, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
This trial will enroll patients with severe hemophilia A. Experiments will be run in vitro by spiking patients' blood with different molecules (currently used and theoretically proposed as adjunctive therapy to emicizumab), therefore no more than minimal direct risk to patients is expected. This is a pilot preclinical study.
Detailed Description
The study aims to determine the hemostatic effect of different Factor IX (FIX) concentrates when added to the plasma of patients on emicizumab prophylaxis and compare it to the hemostatic effect obtained with the addition of bypassing agents (activated prothrombin complex aPCC, and recombinant VIIa rVIIA, recombinant porcine FVIII).
The investigators will study the hemostatic effect using Thrombin Generation assay (CAT) in the presence of different concentrations of FIX concentrates. The investigators will compare the hemostatic effect of added FIX to the effect of added bypassing agents (activated prothrombin complex aPCC, and recombinant VIIa rVIIA, recombinant porcine FVIII)
Plasma will be collected from patients with hemophilia A and inhibitors treated with Emicizumab, a group of plasma samples will be spiked with different concentrations of Factor IX. Thrombin generation profiles will be obtained using CAT.
Another group of plasma samples will be spiked with different concentrations of by passing agents (activated prothrombin complex aPCC, and recombinant VIIa rVIIA, recombinant porcine FVIII). Thrombin generation profiles will be obtained using CAT.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemophilia A
Keywords
Hemophilia A with inhibitors, In vitro, Emicizumab
7. Study Design
Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Open Label
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patient Group
Arm Type
Experimental
Arm Description
In vitro spiking experiments will be realized in plasmas from patients with severe haemophilia A on emicizumab using increasing concentrations of factor IX (rFIX), Activated prothrombin complex (aPCC) and recombinant VIIa (rFVIIa).
Intervention Type
Drug
Intervention Name(s)
Factor IX
Intervention Description
Factor IX is on of the substrates of emicizumab.
Primary Outcome Measure Information:
Title
Determine the homeostatic effect of adding Factor IX concentrate to the plasma of patients with Hemophilia A with inhibitors on emicizumab using peak thrombin
Description
Peak thrombin is a thrombin generation profile. The investigators will compare the peak thrombin obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with aPCC and rFVIIa on emicizumab prophylaxis.
Time Frame
1 Year
Title
Determine the hemostatic effect of Factor IX concentrates and recombinant porcine FVIII when added to the plasma of patients with Hemophilia A with inhibitors on emicizumab using peak thrombin
Description
The investigators will compare the peak thrombin obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with recombinant porcine FVIII on emicizumab prophylaxis.
Time Frame
1 Year
Title
Determine the homeostatic effect of adding Factor IX concentrate to the plasma of patients with Hemophilia A with inhibitors on emicizumab using Endogenous Thrombin Potential (ETP)
Description
Endogenous Thrombin Potential is a thrombin generation profile. The investigators will compare the Endogenous Thrombin Potential obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with aPCC and rFVIIa on emicizumab prophylaxis.
Time Frame
1 Year
Title
Determine the hemostatic effect of Factor IX concentrates and recombinant porcine FVIII when added to the plasma of patients with Hemophilia A with inhibitors on emicizumab using Endogenous Thrombin Potential (ETP)
Description
The investigators will compare the Endogenous Thrombin Potential obtained when spiking patient's plasma with Factor IX concentrates to that obtained when spiking patient's plasma with recombinant porcine FVIII on emicizumab prophylaxis.
Time Frame
1 Year
10. Eligibility
Sex
Male
Gender Based
Yes
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
120 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Signed Informed Consent/Assent Form
Male patients, Age 12 years and older at time of signing Informed Consent Form
Ability to comply with the study protocol, in the investigator's judgment
Diagnosis of severe hemophilia A and are receiving emicizumab prophylaxis, on a weekly maintenance regimen
Exclusion Criteria:
Not able to sign consent
Not willing to provide extra blood for the experiments.
Patients carrying the diagnoses of other coagulopathies in addition to hemophilia A
Patients that have received any hemostatic agent within 5 half-lives of the blood draw. This applies to any agent that might have been used for any reason prior to the blood draw and might affect the global hemostasis.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maissa Janbain, MD, MS
Phone
504-988-8840
Email
mjanbain@tulane.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Radia Ksayer, MD
Phone
914-841-9765
Email
rksayer@tulane.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Maissa Janbain, MD, MS
Organizational Affiliation
Tulane University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tulane University Lakeside Hospital and Clinics
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70001
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maissa Janbain, MD, MS
Phone
504-988-8840
Email
mjanbain@tulane.edu
First Name & Middle Initial & Last Name & Degree
Radia Ksayer, MD
Phone
914-841-9765
Email
rksayer@tulane.edu
First Name & Middle Initial & Last Name & Degree
Maissa Janbain, MD, MS
First Name & Middle Initial & Last Name & Degree
Cindy Leissinger, MD
Facility Name
University Medical Center New Orleans
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maissa Janbain, MD, MS
Phone
504-988-8840
Email
mjanbain@tulane.edu
First Name & Middle Initial & Last Name & Degree
Radia Ksayer, MD
Phone
914-841-9765
Email
rksayer@tulane.edu
First Name & Middle Initial & Last Name & Degree
Maissa Janbain, MD, MS
First Name & Middle Initial & Last Name & Degree
Cindy Leissinger, MD
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
We'll reach out to this number within 24 hrs